Effector Therapeutics Inc Stock Price, News & Analysis

eFFECTOR Therapeutics (NASDAQ: EFTR) reported encouraging interim results from its Phase 1/2 zotatifin trial at ASCO 2022, showing the drug is generally well-tolerated with clinical activity signals in ER+ breast cancer patients. They appointed Doug Warner as Chief Medical Officer to bolster clinical development. Financially, the company holds $41 million in cash as of June 30, 2022, down from $45.7 million in March. R&D expenses rose to $6.9 million, driven by increased development costs, while net loss widened to $6.9 million compared to $5.5 million a year prior.

eFFECTOR Therapeutics (NASDAQ: EFTR) announced its participation in the JMP Securities Life Sciences Conference, scheduled for June 15-16, 2022. The company will host a fireside chat at 10:30 AM ET on June 15 and will hold 1x1 investor meetings throughout the conference. A live webcast will be available on their website, with a replay accessible for 30 days after the event. eFFECTOR is focused on developing selective translation regulator inhibitors (STRIs) for cancer treatment, including tomivosertib, currently in a Phase 2b trial for metastatic non-small cell lung cancer.

eFFECTOR Therapeutics (NASDAQ: EFTR) announced positive interim results from its Phase 1/2 trial of zotatifin, an eIF4A inhibitor for treating solid tumors, particularly ER+ breast cancer. Initial findings show zotatifin was well tolerated, with no severe treatment-related adverse events. Two partial responses were noted in heavily pretreated ER+ patients, indicating potential efficacy. The company plans to expand the study in patients with Cyclin D1 amplification and anticipates reporting additional data by the end of 2022 and early 2023.

eFFECTOR Therapeutics (NASDAQ: EFTR) announced promising interim results from its ongoing Phase 1/2 trial of zotatifin, a selective mRNA helicase inhibitor for various solid tumors. The data, to be presented at the 2022 ASCO Annual Meeting on June 5, indicates that zotatifin is well-tolerated and achieves pharmacologically relevant exposure levels. The company reports reductions in target proteins and initial positive responses in expansion cohorts for ER+ breast cancer and KRAS G12C non-small cell lung cancer. A detailed investor call will discuss further developments.

eFFECTOR Therapeutics (NASDAQ: EFTR) reported Q1 2022 financial results, highlighting a net income of $3.1 million, compared to a net loss of $6.6 million in Q1 2021. The company plans to present data from its Phase 1/2 trial of zotatifin at ASCO 2022 and is expanding its development. Executed a $50 million investment agreement to support clinical programs. As of March 31, cash and equivalents totaled $45.7 million. R&D expenses decreased to $3.1 million, while G&A expenses rose to $3.4 million due to increased public company costs.

eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on cancer treatments, will participate in two key investor conferences. The management team is set to host a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 18 at 1:35 PM EDT. Additionally, they will present at the H.C. Wainwright Global Investment Conference on May 24 at 2:00 PM EDT. Live webcasts will be available on the company's website, with replays accessible for 30 days.

eFFECTOR Therapeutics (NASDAQ: EFTR) announced the resignation of its chief medical officer, Premal Patel, M.D., Ph.D., to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., a current clinical advisor, will expand his role as senior clinical development advisor during the search for a new CMO. Dr. Sikorski's extensive experience and familiarity with eFFECTOR's selective translation regulator inhibitor (STRI) development programs will guide the clinical development of tomivosertib and zotatifin. Dr. Patel will remain as a consultant until September 30, 2022.

eFFECTOR Therapeutics (NASDAQ: EFTR) reported its 2021 financial results, showcasing a significant leap in cash resources to $49.7 million from $15.2 million in 2020. The company achieved a net income of $19 million for Q4 2021, contrasting with a net loss of $5.9 million in Q4 2020. Key developments included advancing tomivosertib and zotatifin into Phase 2 trials and an investment agreement for up to $50 million with Lincoln Park Capital. The KICKSTART trial for tomivosertib has an anticipated $9 billion market opportunity, with topline data expected in H1 2023.

eFFECTOR Therapeutics (NASDAQ: EFTR) appointed Kristen Harrington-Smith to its board, bringing in over 20 years of experience in oncology and drug commercialization, previously at ImmunoGen and Novartis. Her expertise is expected to positively impact the company’s pipeline and product strategy. Concurrently, Jonathan Root resigned from the board, having served for nearly a decade. eFFECTOR specializes in selective translation regulator inhibitors targeting cancer pathways, with ongoing clinical trials for its lead candidate, tomivosertib, in non-small cell lung cancer.